Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience

References

• Mastorino L, Rosset F, Gelato F, et al. Chronic pruritus in atopic patients treated with dupilumab: real life response and related parameters in 354 patients. Pharmaceuticals (Basel). 2022;15(7):1. PMID: 35890180; PMCID: PMC9318403. doi:10.3390/ph15070883.
   Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–4. Epub 2016 Sep 30. PMID: 27690741. doi:10.1056/NEJMoa1610020.
   PubMed Web of Science ®Google Scholar
• Cork MJ, Eckert L, Simpson EL, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatol Treat. 2020;31(6):606–614. Epub 2019 Jun 9. PMID: 31179791. doi:10.1080/09546634.2019.1612836.
   PubMed Web of Science ®Google Scholar
• Miniotti M, Ribero S, Mastorino L, et al. Long-term psychological outcome of patients with moderate-to-severe atopic dermatitis continuously treated with Dupilumab: data up to 3 years. Exp Dermatol. 2023;32(6):852–858. Epub 2023 Mar 10. PMID: 36856013. doi:10.1111/exd.14786.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449. Epub 2020 Dec 30. PMID: 33000465; PMCID: PMC7986411. doi:10.1111/bjd.19574.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450–463. Epub 2021 Feb 22. PMID: 33000503; PMCID: PMC7986183. doi:10.1111/bjd.19573.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Wollenberg A, Soong W, et al. Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3). Ann Allergy Asthma Immunol. 2022;129(5):592–604.e5. Epub 2022 Jul 14. PMID: 35843520. doi:10.1016/j.anai.2022.07.007.
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Vignoli CA, et al. Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience. J Dermatol Treat. 2023;34(1):2216815. PMID: 37246920. doi:10.1080/09546634.2023.2216815.
   PubMed Web of Science ®Google Scholar
• Pezzolo E, Schena D, Gambardella A, et al. Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study. J Eur Acad Dermatol Venereol. 2023. Epub ahead of print. PMID: 37483150. doi:10.1111/jdv.19382.
   Google Scholar
• Reich A, Heisig M, Phan NQ, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92(5):497–501. PMID: 22102095. doi:10.2340/00015555-1265.
   PubMed Web of Science ®Google Scholar
• Charman CR, Venn AJ, Ravenscroft JC, et al. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326–1332. PMID: 24024631; PMCID: PMC3920642.] doi:10.1111/bjd.12590.
   PubMed Web of Science ®Google Scholar
• Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2020;36(3):367–376. Epub 2019 Dec 12. PMID: 31778083. doi:10.1080/03007995.2019.1699516.
   PubMed Web of Science ®Google Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659–664. PMID: 16185263. doi:10.1111/j.0022-202X.2005.23621.x.
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. PMID: 6880820. doi:10.1111/j.1600-0447.1983.tb09716.x.
   PubMed Web of Science ®Google Scholar
• Gutermuth J, Pink AE, Worm M, et al. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III ­clinical trial (ECZTRA 7). Br J Dermatol. 2022;186(3):440–452. doi:10.1111/bjd.20832.
   PubMed Web of Science ®Google Scholar